241 related articles for article (PubMed ID: 28399409)
1. Direct Pharmacological Targeting of a Mitochondrial Ion Channel Selectively Kills Tumor Cells In Vivo.
Leanza L; Romio M; Becker KA; Azzolini M; Trentin L; Managò A; Venturini E; Zaccagnino A; Mattarei A; Carraretto L; Urbani A; Kadow S; Biasutto L; Martini V; Severin F; Peruzzo R; Trimarco V; Egberts JH; Hauser C; Visentin A; Semenzato G; Kalthoff H; Zoratti M; Gulbins E; Paradisi C; Szabo I
Cancer Cell; 2017 Apr; 31(4):516-531.e10. PubMed ID: 28399409
[TBL] [Abstract][Full Text] [Related]
2. Targeting the Potassium Channel Kv1.3 Kills Glioblastoma Cells.
Venturini E; Leanza L; Azzolini M; Kadow S; Mattarei A; Weller M; Tabatabai G; Edwards MJ; Zoratti M; Paradisi C; Szabò I; Gulbins E; Becker KA
Neurosignals; 2017; 25(1):26-38. PubMed ID: 28869943
[TBL] [Abstract][Full Text] [Related]
3. Inhibitors of mitochondrial Kv1.3 channels induce Bax/Bak-independent death of cancer cells.
Leanza L; Henry B; Sassi N; Zoratti M; Chandy KG; Gulbins E; Szabò I
EMBO Mol Med; 2012 Jul; 4(7):577-93. PubMed ID: 22496117
[TBL] [Abstract][Full Text] [Related]
4. Correlation between potassium channel expression and sensitivity to drug-induced cell death in tumor cell lines.
Leanza L; O'Reilly P; Doyle A; Venturini E; Zoratti M; Szegezdi E; Szabo I
Curr Pharm Des; 2014; 20(2):189-200. PubMed ID: 23701546
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological modulation of Kv1.3 potassium channel selectively triggers pathological B lymphocyte apoptosis in vivo in a genetic CLL model.
Severin F; Urbani A; Varanita T; Bachmann M; Azzolini M; Martini V; Pizzi M; Tos APD; Frezzato F; Mattarei A; Ghia P; Bertilaccio MTS; Gulbins E; Paradisi C; Zoratti M; Semenzato GC; Leanza L; Trentin L; Szabò I
J Exp Clin Cancer Res; 2022 Feb; 41(1):64. PubMed ID: 35172855
[TBL] [Abstract][Full Text] [Related]
6. Tumor-reducing effect of the clinically used drug clofazimine in a SCID mouse model of pancreatic ductal adenocarcinoma.
Zaccagnino A; Managò A; Leanza L; Gontarewitz A; Linder B; Azzolini M; Biasutto L; Zoratti M; Peruzzo R; Legler K; Trauzold A; Kalthoff H; Szabo I
Oncotarget; 2017 Jun; 8(24):38276-38293. PubMed ID: 27542263
[TBL] [Abstract][Full Text] [Related]
7. Voltage-Gated Potassium Channels Kv1.3--Potentially New Molecular Target in Cancer Diagnostics and Therapy.
Teisseyre A; Gąsiorowska J; Michalak K
Adv Clin Exp Med; 2015; 24(3):517-24. PubMed ID: 26467143
[TBL] [Abstract][Full Text] [Related]
8. Selective toxicity of persian gulf sea cucumber holothuria parva on human chronic lymphocytic leukemia b lymphocytes by direct mitochondrial targeting.
Salimi A; Motallebi A; Ayatollahi M; Seydi E; Mohseni AR; Nazemi M; Pourahmad J
Environ Toxicol; 2017 Apr; 32(4):1158-1169. PubMed ID: 27404045
[TBL] [Abstract][Full Text] [Related]
9. Clofazimine, Psora-4 and PAP-1, inhibitors of the potassium channel Kv1.3, as a new and selective therapeutic strategy in chronic lymphocytic leukemia.
Leanza L; Trentin L; Becker KA; Frezzato F; Zoratti M; Semenzato G; Gulbins E; Szabo I
Leukemia; 2013 Aug; 27(8):1782-5. PubMed ID: 23426166
[No Abstract] [Full Text] [Related]
10. Pharmacological targeting of the mitochondrial calcium-dependent potassium channel KCa3.1 triggers cell death and reduces tumor growth and metastasis in vivo.
Bachmann M; Rossa A; Varanita T; Fioretti B; Biasutto L; Milenkovic S; Checchetto V; Peruzzo R; Ahmad SA; Patel SH; Lukowski R; Edwards MJ; Ceccarelli M; Gulbins E; Zoratti M; Mattarei A; Szabo I
Cell Death Dis; 2022 Dec; 13(12):1055. PubMed ID: 36539400
[TBL] [Abstract][Full Text] [Related]
11. Selective Anticancer Activity of Acacetin Against Chronic Lymphocytic Leukemia Using Both In Vivo and In Vitro Methods: Key Role of Oxidative Stress and Cancerous Mitochondria.
Salimi A; Roudkenar MH; Sadeghi L; Mohseni A; Seydi E; Pirahmadi N; Pourahmad J
Nutr Cancer; 2016; 68(8):1404-1416. PubMed ID: 27779444
[TBL] [Abstract][Full Text] [Related]
12. Targeting a mitochondrial potassium channel to fight cancer.
Leanza L; Venturini E; Kadow S; Carpinteiro A; Gulbins E; Becker KA
Cell Calcium; 2015 Jul; 58(1):131-8. PubMed ID: 25443654
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological evaluation of chalcones as inhibitors of the voltage-gated potassium channel Kv1.3.
Cianci J; Baell JB; Flynn BL; Gable RW; Mould JA; Paul D; Harvey AJ
Bioorg Med Chem Lett; 2008 Mar; 18(6):2055-61. PubMed ID: 18289849
[TBL] [Abstract][Full Text] [Related]
14. Mitochondrial Kv1.3: a New Target in Cancer Biology?
Checchetto V; Prosdocimi E; Leanza L
Cell Physiol Biochem; 2019; 53(S1):52-62. PubMed ID: 31854954
[TBL] [Abstract][Full Text] [Related]
15. Design and characterization of a novel structural class of Kv1.3 inhibitors.
Hendrickx LA; Dobričić V; Toplak Ž; Peigneur S; Mašič LP; Tomašič T; Tytgat J
Bioorg Chem; 2020 May; 98():103746. PubMed ID: 32199306
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and cellular effects of a mitochondria-targeted inhibitor of the two-pore potassium channel TASK-3.
Bachmann M; Rossa A; Antoniazzi G; Biasutto L; Carrer A; Campagnaro M; Leanza L; Gonczi M; Csernoch L; Paradisi C; Mattarei A; Zoratti M; Szabo I
Pharmacol Res; 2021 Feb; 164():105326. PubMed ID: 33338625
[TBL] [Abstract][Full Text] [Related]
17. The effects of Kv1.3 and IKCa1 potassium channel inhibition on calcium influx of human peripheral T lymphocytes in rheumatoid arthritis.
Toldi G; Bajnok A; Dobi D; Kaposi A; Kovács L; Vásárhelyi B; Balog A
Immunobiology; 2013 Mar; 218(3):311-6. PubMed ID: 22705192
[TBL] [Abstract][Full Text] [Related]
18. Targeting the Mitochondrial Potassium Channel Kv1.3 to Kill Cancer Cells: Drugs, Strategies, and New Perspectives.
Prosdocimi E; Checchetto V; Leanza L
SLAS Discov; 2019 Oct; 24(9):882-892. PubMed ID: 31373829
[TBL] [Abstract][Full Text] [Related]
19. 3-Alkyl- and 3-aryl-7H-furo[3,2-g]chromen-7-ones as blockers of the voltage-gated potassium channel Kv1.3.
Wernekenschnieder A; Körner P; Hänsel W
Pharmazie; 2004 Apr; 59(4):319-20. PubMed ID: 15125582
[TBL] [Abstract][Full Text] [Related]
20. Design and Synthesis of Novel Reactive Oxygen Species Inducers for the Treatment of Pancreatic Ductal Adenocarcinoma.
Kuang Y; Sechi M; Nurra S; Ljungman M; Neamati N
J Med Chem; 2018 Feb; 61(4):1576-1594. PubMed ID: 29328656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
